Latest Stocks: Alliqua Biomedical Inc (ALQA) Stock Rating Lowered by ValuEngine

Latest Stocks: Alliqua Biomedical Inc (ALQA) Stock Rating Lowered by ValuEngine

Alliqua Biomedical Inc (NASDAQ:ALQA) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Friday.

A number of other research firms also recently weighed in on ALQA. Chardan Capital decreased their target price on shares of Alliqua Biomedical from $2.00 to $1.25 and set a “buy” rating for the company in a research report on Wednesday, March 8th. Zacks Investment Research raised shares of Alliqua Biomedical from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a research report on Thursday, March 16th. HC Wainwright reissued a “buy” rating and set a $1.50 target price (down previously from $2.50) on shares of Alliqua Biomedical in a research report on Friday, April 7th. Finally, Cowen and Company reissued an “outperform” rating and set a $1.50 target price on shares of Alliqua Biomedical in a research report on Tuesday, April 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $1.31.

In other news, COO Bradford Barton bought 75,000 shares of the firm’s stock in a transaction on Monday, April 3rd. The stock was acquired at an average price of $0.40 per share, with a total value of $30,000.00. Following the transaction, the chief operating officer now owns 320,643 shares of the company’s stock, valued at approximately $128,257.20. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider David Ian Johnson bought 250,000 shares of the firm’s stock in a transaction on Monday, April 3rd. The shares were purchased at an average cost of $0.40 per share, with a total value of $100,000.00. Following the transaction, the insider now directly owns 1,194,535 shares in the company, valued at approximately $477,814. The disclosure for this purchase can be found here. Insiders have acquired a total of 387,500 shares of company stock valued at $155,000 in the last three months. Insiders own 15.20% of the company’s stock. A number of hedge funds have recently added to or reduced their stakes in ALQA. Perceptive Advisors LLC increased its stake in Alliqua Biomedical by 120.3% in the first quarter. Perceptive Advisors LLC now owns 4,233,951 shares of the company’s stock worth $2,136,000 after buying an additional 2,312,000 shares in the last quarter. Sabby Management LLC boosted its position in Alliqua Biomedical by 93.7% in the first quarter. Sabby Management LLC now owns 2,131,050 shares of the company’s stock worth $1,076,000 after buying an additional 1,030,652 shares during the last quarter. KCG Holdings Inc. boosted its position in Alliqua Biomedical by 777.7% in the first quarter. KCG Holdings Inc. now owns 525,077 shares of the company’s stock worth $265,000 after buying an additional 465,256 shares during the last quarter. Renaissance Technologies LLC boosted its position in Alliqua Biomedical by 54.2% in the first quarter. Renaissance Technologies LLC now owns 632,800 shares of the company’s stock worth $319,000 after buying an additional 222,400 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Alliqua Biomedical by 5.3% in the first quarter. Vanguard Group Inc. now owns 449,715 shares of the company’s stock worth $227,000 after buying an additional 22,643 shares during the last quarter. 29.90% of the stock is owned by institutional investors and hedge funds.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Related posts

Leave a Comment